Active — Not RecruitingPhase 2

Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

United States29 participantsStarted 2018-10-18

Plain-language summary

This research study is studying an immune-based cancer drug as a possible treatment for prostate cancer. The drug involved in this study is: -Nivolumab

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓Archival tissue is mandatory, either prostatectomy specimen or (in patients who received primary RT) diagnostic core biopsies. Patients must consent to next-generation sequencing performed on this tissue.
✓Renal

What they're measuring

Disease Control Rate at 12 Weeks

Timeframe: 12 weeks

Trial details

NCT IDNCT03637543

SponsorBeth Israel Deaconess Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-09-30

Results submitted2026-03-30

View on ClinicalTrials.gov More Prostate Cancer trials